Dr. Linnea I. Chap, MD

Dr. Chap practices at Westwood Eye Surgical Institute, Inc. in Beverly Hills, California.

Dr. Chap's NPI, 1700839362, was assigned on May 17, 2006. Dr. Chap graduated from University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) in 1988. Dr. Chap holds California license G73680.

Dr. Chap's primary practice is Westwood Eye Surgical Institute, Inc., at 8900 Wilshire Blvd, Beverly Hills, CA 90211 in Los Angeles County. The practice phone is (310) 474-2010.

Dr. Chap's primary practice is Westwood Eye Surgical Institute, Inc. in Beverly Hills, California. Dr. Chap is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is Beverly Hills Cancer Center. Dmand AI also links Dr. Chap to 2 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chap practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Chap's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Chap is licensed in California.

CMS data shows 7,174 Medicare services from Dr. Chap across 13 procedure codes in 2024, for 191 Medicare patients. Medicare paid $165,839 for them. Every service was in an office.

CMS counts 191 Medicare patients who saw Dr. Chap in 2024. The largest group is 65 to 74, with 118 patients. 75% of them have cancer, and 67% have high cholesterol. 46% are also on Medicaid. Their average risk score is 1.17, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Chap's median patient age at 63, with 99% women.

In 2024, Dr. Chap wrote 1,011 Medicare Part D claims for 134 patients. 82% of them were for generic drugs. CMS names the drug for 839 of them, across 25 drugs with 11 or more claims each, at $1,370,205 in total drug cost. In 2023, CMS named 826 claims across 24 drugs.

Dr. Chap accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chap as offering telehealth.

Dmand AI links 3 papers to Dr. Chap, published from 2012 to 2025. Dr. Chap has published most often in Nat Commun. Dr. Chap's most frequent co-authors are Pavani Chalasani, MD, William J. Gradishar, MD and Jason Michael Melear, MD.

Dmand AI links Dr. Chap to 6 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Ductal, Breast. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Chap that name 2 trials.

CMS Open Payments shows 1,993 general payments to Dr. Chap from 94 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 63% of the total. Pfizer Inc. paid the most, $261,637. It also lists 9 research payments totaling $11,004 from 2017 to 2023, naming 2 clinical trials.

Dr. Chap graduated from University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) in 1988.